Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer

Trends in Endocrinology and Metabolism

Volumn 21, Issue 5, 2010, Pages 315-324

  Knudsen, Karen E ^a   Penning, Trevor M ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; DOCETAXEL; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HYDROXYSTEROID DEHYDROGENASE; INDOMETACIN; KETOCONAZOLE; LEUPRORELIN; MDV 3100; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR RECEPTOR COACTIVATOR 2; NUCLEAR RECEPTOR COREPRESSOR; PARATHYROID HORMONE RELATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN MDM2; RD 162; SOMATOMEDIN C; STEROID 17ALPHA MONOOXYGENASE; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; SUMO 1 PROTEIN; TOK 001; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; BONE METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASTRATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; CASTRATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 77952554163     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.01.002     Document Type: Review

References (95)

1. Jemal A., et al. Cancer statistics. CA Cancer J. Clin. 2008, 58:71-96.
2. Klein E.A., et al. Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?. Urol. Oncol. 2009, 27:67-71.
3. Klotz L. Combined androgen blockade: an update. Urol. Clin. North Am. 2006, 33:161-166. v-vi.
4. Knudsen K.E., Scher H.I. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res. 2009, 15:4792-4798.
5. Loblaw D.A., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 2007, 25:1596-1605.
6. Taplin M.E. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol. 2007, 4:236-244.
7. Chen Y., et al. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 2008, 8:440-448.
8. Attar R.M., et al. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin. Cancer Res. 2009, 15:3251-3255.
9. Yuan X., Balk S.P. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol. 2009, 27:36-41.
10. Claessens F., et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal 2008, 6:e008.
11. Centenera M.M., et al. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol. 2008, 22:2373-2382.
12. Penning T.M., et al. Pre-receptor regulation of the androgen receptor. Mol. Cell Endocrinol. 2008, 281:1-8.
13. Chmelar R., et al. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 2007, 120:719-733.
14. Agoulnik I.U., Weigel N.L. Androgen receptor coactivators and prostate cancer. Adv. Exp. Med. Biol. 2008, 17:245-255.
15. Balk S., Knudsen K. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. Atlas (NURSA) 2008, 6:e001.
16. Beekman K.W., Hussain M. Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urol. Oncol. 2008, 26:415-419.
17. Ryan C.J., et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 2006, 68:834-839.
18. Wang Q., et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 2007, 27:380-392.
19. Wang Q., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
20. Cai C., et al. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009, 69:6027-6032.
21. Lin C., et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 39:1069-1083.
22. Mani R.S., et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
23. van Poppel H., Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?. Urology 2008, 71:1001-1006.
24. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J. Urol. 1998, 160:1685-1688.
25. Shang Y., et al. Formation of the androgen receptor transcription complex. Mol. Cell 2002, 9:601-610.
26. Agus D.B., et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. 1999, 91:1869-1876.
27. De Dosso S., Berthold D.R. Docetaxel in the management of prostate cancer: current standard of care and future directions. Expert Opin. Pharmacother. 2008, 9:1969-1979.
28. Linja M.J., et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
29. Latil A., et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001, 61:1919-1926.
30. Ford O.H., et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 2003, 170:1817-1821.
31. Edwards J., et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 2003, 89:552-556.
32. Brown R.S., et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol. 2002, 198:237-244.
33. Wang L.G., et al. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex. Cancer Res. 2008, 68:2678-2688.
34. Stanbrough M., et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10823-10828.
35. Han G., et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1151-1156.
36. Chen C.D., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
37. Brooke G.N., Bevan C.L. The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics 2009, 10:18-25.
38. Scher H.I., Kelly W.K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 1993, 11:1566-1572.
39. Middleman M.N., et al. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Pharmacotherapy 1996, 16:376-381.
40. Hara T., et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003, 63:149-153.
41. Steinkamp M.P., et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009, 69:4434-4442.
42. Dehm S.M., et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68:5469-5477.
43. Hu R., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69:16-22.
44. Guo Z., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69:2305-2313.
45. Jenster G., et al. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 1995, 270:7341-7346.
46. Faus H., Haendler B. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 2006, 60:520-528.
47. McCall P., et al. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br. J. Cancer 2008, 98:1094-1101.
48. Ponguta L.A., et al. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J. Biol. Chem. 2008, 283:20989-21001.
49. Zhu M.L., Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 2008, 15:841-849.
50. Chi K.N., et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur. Urol. 2009, 56:594-605.
51. Guo Z., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006, 10:309-319.
52. DaSilva J., et al. The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res. 2009, 69:7402-7411.
53. Kung H.J., Evans C.P. Oncogenic activation of androgen receptor. Urol. Oncol. 2009, 27:48-52.
54. Chen S., et al. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J. Biol. Chem. 2009, 284:25576-25584.
55. Xu K., et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 2009, 15:270-282.
56. Miyajima N., et al. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res. 2008, 68:3486-3494.
57. Gaughan L., et al. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res. 2005, 3:13-26.
58. Kaikkonen S., et al. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol. Endocrinol. 2009, 23:292-307.
59. Xu J., et al. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 2009, 9:615-630.
60. Gregory C.W., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61:4315-4319.
61. Agoulnik I.U., et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005, 65:7959-7967.
62. Burd C.J., et al. Androgen receptor corepressors and prostate cancer. Endocr. Relat. Cancer 2006, 13:979-994.
63. Dai Y., et al. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 2008, 29:1725-1733.
64. Dart D., et al. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr. Relat. Cancer 2009, 16:1157-1169.
65. Zhu P., et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006, 124:615-629.
66. Belandia B., et al. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol. Cell Biol. 2005, 25:1425-1436.
67. Zhang Y., et al. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol. Cancer Ther. 2008, 7:3176-3186.
68. Knudsen K.E. The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div. 2006, 1:15.
69. Comstock C.E., et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin. Cancer Res. 2009, 15:5338-5349.
70. Russell D.W., Wilson J.D. Steroid 5α-reductase two genes/two enzymes. Annu. Rev. Biochem. 1994, 63:25-61.
71. Labrie F., et al. " Intracrinology" autonomy and freedom of peripheral tissues. Ann. Endocrinol. (Paris) 1995, 56:23-29.
72. Labrie F., et al. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 2000, 25:1-16.
73. Penning T.M., et al. Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors. Mol. Cell Endocrinol. 2006, 248:182-191.
74. Locke J., et al. Androgen levels increase by intratumoral de novo steroidogenesis during the progression of castration-resistant prostate cancer. Cancer Res. 2008, 68:6407-6415.
75. Montgomery R.B., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68:4447-4454.
76. Stanbrough M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
77. Thompson I.M., et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349:215-224.
78. Tran C., et al. Development of a second-generation antiandrogen for the treatment of advanced prostate cancer. Science 2009, 324:787-790.
79. Redman M., et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. 2008, 1:174-181.
80. Rittmaster R.S. 5a-Reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:389-402.
81. Bauman D.R., et al. Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α,17β-diol to 5α-dihydrotestosterone: A potential therapeutic target for androgen dependent disease. Mol. Endocrinol. 2006, 20:444-458.
82. Nickel J.C. Comparison of clinical trials with finasteride and dutasteride. Rev. Urol. 2004, 6(Suppl):S31-S39.
83. Wurzel R., et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007, 10:149-154.
84. Auchus R. The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab 2004, 15:432-438.
85. Penning T.M., et al. Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor. Mol. Cell Endocrinol. 2007, 265-66:77-82.
86. Locke J.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008, 68:6407-6415.
87. Leon C.G. et al. (2009)Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate (). http://www3.interscience.wiley.com/journal/34304/home.
88. Locke J.A. et al. (2009)Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate (). http://www3.interscience.wiley.com/journal/34304/home.
89. Attard G., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 2008, 26:4563-4571.
90. Sartor O., et al. Activity of dutasteride plus ketoconazole in csatration-refractory prostate cancer after progression on ketoconazole alone. Clin. Genitourin. Cancer 2009, 7:E90-92.
91. Andersson S., et al. The molecular biology of androgenic 17β-hydroxysteroid dehydrogenases. J. Steroid Biochem. Mol. Biol. 1995, 53:37-39.
92. Andersson S.G., et al. Molecular genetics and pathophysiology of 17β-hydroxysteroid dehydrogenase 3 deficiency. J. Clin. Endocrinol. Metab. 1996, 81:130-136.
93. Byrns M., et al. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 2008, 75:484-493.
94. Vasaitis T., et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol. Cancer Ther. 2008, 7:2348-2357.
95. Penning T.M., Drury J.E. Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphism. Arch. Biochem. Biophys. 2007, 464:241-250.